A twice-yearly shot gets a cheaper twin
The U.S. Food and Drug Administration has approved a generic version of lenacapavir, the only HIV prevention drug given as two injections a year. The decision is a step toward selling the shot at low cost in 120 low- and middle-income countries across sub-Saharan Africa, Asia and Latin America.
The approval is labelled tentative, the FDA's standard status for a generic while the original product is still under patent. It is granted under a long-standing arrangement meant to guarantee the quality of HIV medicines that the U.S. government buys and supplies to other countries. In practice, it tells regulators elsewhere that the generic has met a stringent review.
Why supply has been the problem
Until now Gilead Sciences has been the only supplier. Demand has run ahead of supply in poorer countries even though the company signed royalty-free licences with six generic manufacturers and promised to supply the drug at no profit while generic production ramps up. Those licences cover a specific list of countries, not the whole world.
Health ministries have complained about waiting lists and about the gap between what donors can pay and what a branded product costs. A generic version made by a licensed manufacturer can be priced far lower, especially once several plants are running.
What patients and clinics gain
Lenacapavir for prevention is given every six months, which removes the need for a daily pill. Trials showed close to full protection in the groups studied. For people who struggle to take a tablet every day, or who face stigma when collecting pills, the shot has been the most anticipated option in years.
Price estimates circulating among donors put the generic at about $40 a person a year once volume production begins. That is a fraction of the branded price in high-income markets.
The work still ahead
Approval in the United States does not put the product on shelves in Africa. Each country still needs its own regulatory sign-off, and health systems need cold chains, trained staff and clinics able to schedule repeat visits every six months. Funding agencies must also decide how to pay for a prevention method that has no track record at scale.
UNAIDS and treatment advocates welcomed the decision but said the real test is delivery. The first generic shipments are expected to reach licensed markets over the coming months, with wider distribution depending on how fast national approvals follow.